Epizyme Inc (NASDAQ:EPZM)

0.4585
BATS BZX Real-Time Price
As of 2:03pm ET
 -0.0224 / -4.66%
Today’s Change
0.43
Today|||52-Week Range
9.86
-81.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$84.0M

Company Description

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Contact Information

Epizyme, Inc.
400 Technology Square
Cambridge Massachusetts 02139
P:(617) 229-5872
Investor Relations:

Employees

Shareholders

Other institutional62.40%
Mutual fund holders23.41%
Individual stakeholders18.31%

Top Executives

Grant C. BoglePresident, Chief Executive Officer, CFO & Director
Jerald KornChief Operating Officer
Jeffery L. KutokChief Scientific Officer & Executive VP
John F. WeidenbruchSecretary, Senior Vice President & General Counsel
Rebecca MehrwerthSVP & Head-Commercial